1. Home
  2. TXMD vs SNGX Comparison

TXMD vs SNGX Comparison

Compare TXMD & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TXMD
  • SNGX
  • Stock Information
  • Founded
  • TXMD 2008
  • SNGX 1987
  • Country
  • TXMD United States
  • SNGX United States
  • Employees
  • TXMD N/A
  • SNGX N/A
  • Industry
  • TXMD Biotechnology: Pharmaceutical Preparations
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TXMD Health Care
  • SNGX Health Care
  • Exchange
  • TXMD Nasdaq
  • SNGX Nasdaq
  • Market Cap
  • TXMD 12.3M
  • SNGX 10.1M
  • IPO Year
  • TXMD N/A
  • SNGX 1987
  • Fundamental
  • Price
  • TXMD N/A
  • SNGX $1.81
  • Analyst Decision
  • TXMD
  • SNGX Strong Buy
  • Analyst Count
  • TXMD 0
  • SNGX 1
  • Target Price
  • TXMD N/A
  • SNGX $6.00
  • AVG Volume (30 Days)
  • TXMD 16.0K
  • SNGX 2.7M
  • Earning Date
  • TXMD 11-11-2025
  • SNGX 11-07-2025
  • Dividend Yield
  • TXMD N/A
  • SNGX N/A
  • EPS Growth
  • TXMD N/A
  • SNGX N/A
  • EPS
  • TXMD N/A
  • SNGX N/A
  • Revenue
  • TXMD $2,559,000.00
  • SNGX N/A
  • Revenue This Year
  • TXMD $427.09
  • SNGX N/A
  • Revenue Next Year
  • TXMD N/A
  • SNGX N/A
  • P/E Ratio
  • TXMD N/A
  • SNGX N/A
  • Revenue Growth
  • TXMD 156.93
  • SNGX N/A
  • 52 Week Low
  • TXMD $0.70
  • SNGX $1.09
  • 52 Week High
  • TXMD $2.44
  • SNGX $6.23
  • Technical
  • Relative Strength Index (RSI)
  • TXMD 44.55
  • SNGX 40.84
  • Support Level
  • TXMD $0.99
  • SNGX $1.11
  • Resistance Level
  • TXMD $1.11
  • SNGX $1.88
  • Average True Range (ATR)
  • TXMD 0.03
  • SNGX 0.19
  • MACD
  • TXMD 0.00
  • SNGX -0.01
  • Stochastic Oscillator
  • TXMD 57.85
  • SNGX 32.10

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: